Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 LP.8.1 spike protein RBD fusion homodimer
- Development stage
- Preclinical
- Lead developer
- Hipra
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
SARS-CoV-2 LP.8.1 spike protein RBD fusion homodimer is a recombinant protein subunit vaccine candidate developed by the Finnish Institute for Health and Welfare (THL) in collaboration with the University of Helsinki. The vaccine construct consists of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein fused to a dimerization domain, typically a human IgG1 Fc fragment, which facilitates the formation of a stable homodimer. This dimeric structure is designed to enhance the immunogenicity of the RBD by increasing its size and mimicking the multivalent display of antigens, thereby promoting a more robust B-cell response and the production of high-titer neutralizing antibodies. LP.8.1 is intended for the prevention of COVID-19 infection and has demonstrated potent neutralizing activity against multiple SARS-CoV-2 variants in preclinical studies.
- Other names
- RBD-Fc homodimer vaccineFinnish RBD-fusion vaccineSARS-CoV-2 RBD-homodimer protein vaccineSARS-CoV2 RBD-homodimer protein vaccineSARS-CoV 2 RBD-homodimer protein vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on SARS-CoV-2 LP.8.1 spike protein RBD fusion homodimer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 LP.8.1 spike protein RBD fusion homodimer.